Pasithea Therapeutics Corp. — Director's Dealing 2023

Jun 7, 2023

SEC Form 4/A — Form 4/A

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2022-10-17

Reporting Person: STEINMAN LAWRENCE (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1282174	Direct

Footnotes

F1: On October 17, 2022 (the "Transaction Date"), the Reporting Person filed a Form 4 which misstated the total number of shares of Common Stock beneficially owned by the Reporting Person as of the Transaction Date. The Form 4 inadvertently excluded transactions that were reported on a Form 4 filed by the Reporting Person on June 30, 2022. As reported in this amendment, the Reporting Person beneficially owned 1,282,174 shares of the Issuer's Common Stock as of the Transaction Date.